Endocrinology

Although patients with diabetes who were at high risk for cardiovascular events did not benefit from treatment with lixisenatide, results from the ELIXA study showed that the drug is safe in this population.

Study results show combination treatment with empagliflozin and linagliptin effectively reduced HbA1c in patients with type 2 diabetes mellitus.

Although commercial support for continuing medical education has been on the decline since 2008, it nevertheless continues to be a major revenue source for CME providers and a cause for potential concern.

Obesity contributes to significant morbidity and mortality among primary care patients. This paper summarizes options for pharmacological management of obesity. Medications approved for obesity are Phenteremine/Topiramate, Orlistat, Lorcaserin, Naltrexone/Bupropion, Liraglutide.

As the diabetes epidemic continues to grow doctors are being faced with the task of stopping or reversing the trend.

For patients with diabetes controlling their condition is largely in their hands. How they work the process can determine their overall quality of life.

Alogliptin appears to slow the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus.

As the healthcare landscape has changed in recent years everyone from patients to doctors to pharmaceutical companies have had to change along with it.

When blood glucose levels prove difficult to control in patients with type 2 diabetes mellitus, it may be time to consider adding a third drug to the treatment regimen.

With a complicated condition like diabetes there is more to treatment than finding the right medication for patients. Providing the information they need and direction to help in their daily lives is also a key part of the overall picture.

There are a substantial number of factors physicians must take into consideration before starting a patient with type 2 diabetes mellitus on a particular treatment path. According to results from a recent study, the effectiveness of one of the most popular diabetes medications may be dependent on a patient's race or ethnicity.

With multiple factors hurting patients' chances of reaching type 2 diabetes treatment goals – including a lack of timely follow-up appointments and yo-yo blood glucose (A1C) levels – a respected physician recently advised a major shift in treatment, especially early on in the progressive disease.

Even adults with diabetes may be injecting insulin incorrectly which could put them at higher risk for additional conditions, according to lead author Paula M. Trief, PhD, of SUNY Upstate Medical Center.

With more than 10000 people in Boston for the American Diabetes Association's Scientific Sessions the event provides a chance for some of the top minds in the field to share information.

With so many people affected by diabetes finding the right treatment for the individual patients is becoming a key factor in care.

Pain levels due to diabetic peripheral neuropathy (DPN) may be altered depending on patients' vitamin D levels, a British study. The findings will be presented in a poster session on June 8 at the American Diabetes Association 75th Scientific Sessions in Boston, MA.

DPP-4 inhibitors may also enhance beta cell function in patients with type 2 diabetes mellitus.

Diabetes researchers looked at the impact of chronic kidney disease on the glucose-regulating drug empagliflozin.

Results from a 104-week phase 3 study may have important implications for the way patients with type 2 diabetes mellitus tackle weight loss.

Insulin glargine, a commonly used treatment for type 2 diabetes mellitus, may be more effective when administered at a higher dose, according to results from a phase 3 study.

While medications go through extensive studies and research before being released to patients, the results in a controlled setting versus real-life situations may vary. Or do they?

Study results show that the combination of metformin and glibenclamide is as effective as insulin in achieving glycemic control in women with gestational diabetes and may be a more acceptable and cost effective therapy.

Researchers compared canagliflozin and sitagliptin treatment on HbA1c levels and body weight in patients with type 2 diabetes mellitus.

A rat study shows saxagliptin has promise for renal protection.

Empagliflozin, a diabetes drug that controls glucose levels, may also help ameliorate erectile dysfunction in patients with type 2 diabetes mellitus.

Approved by the US Food and Drug Administration (FDA) just over 4 years ago, linagliptin (Tradjenta) can help protect against renal injury in patients with type 2 diabetes.

Oxidative stress plays an important role in the ability for dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, to effectively ease diabetic nephropathy, according to lead author Takashi Hatanaka of Nagoya University. The study will be presented in a poster session on June 6 at the American Diabetes Association 75th Scientific Sessions in Boston, MA.

The global pandemic of diabetes poses a huge public health challenge to every nation. In 2014 more than 380 million people around the world were living with diabetes-8.3% of the adult population. That number is expected to increase to 592 million by 2035.

Overt hyperthyroidism is a known risk factor for osteoporosis and fractures. More subtle alterations in thyroid function, such as those that occur in subclinical thyroid dysfunction, may also be associated with increased fracture risk and bone loss, but until recently no clinical trials have adequately explored that issue.

A recent Chinese study of antibiotic use in primary care settings found that up to 93% of respiratory tract infections (RTIs) were treated with antibiotics, with more than 60% reported as inappropriate.